trending Market Intelligence /marketintelligence/en/news-insights/trending/e8re44t5yauwmpzh0fap4a2 content esgSubNav
In This List

Basilea Pharmaceutica CEO to retire, board members to step down

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Basilea Pharmaceutica CEO to retire, board members to step down

Swiss drugmaker Basilea Pharmaceutica AG said Ronald Scott will retire as CEO.

David Veitch, Basilea's chief commercial officer, will replace Scott, effective April 19.

Veitch's previous roles include president of European operations at Savient Pharmaceuticals Inc. and senior vice president of Europe, the Middle East and Africa at Bristol-Myers Squibb Pharmaceuticals, a unit of Bristol-Myers Squibb Co.

Further, Daniel Lew and Thomas Rinderknecht will not stand for re-election at Basilea's annual general meeting April 18.